Melanocyte differentiation antigen

The term "melanocyte differentiation antigen" is used to describe a group of proteins expressed by melanocytes and melanoma cells, including MART-1 (Melan-A), gp100 (PMEL), tyrosinase, TRP-1, and TRP-2. These antigens are recognized by the immune system and have been harnessed as diagnostic markers and immunotherapeutic targets in melanoma. The archetypical molecule in this group is MART-1 (Melan-A), a protein involved in melanosome structure and maturation, whose peptide fragments are presented on MHC class I molecules and serve as key targets for melanoma-specific T cells[2]. While immensely useful in melanoma diagnosis and T cell therapy, targeting these antigens carries risks of autoimmunity against normal melanocytes, leading to vitiligo or eye complications. The phrase “melanocyte differentiation antigen” itself is a catch-all and not a unique molecular entity, so for structured, molecule-level data it is necessary to specify the precise antigen member (e.g., “Melan-A” or “PMEL”).

Other names

MART-1 (Melanoma antigen recognized by T cells 1)Melan-AMelanocyte lineage-specific antigengp100 (PMEL)tyrosinaseTRP-1 (TYRP1)TRP-2 (DCT)

Immunotherapeutic targeting: Peptides derived from MART-1/Melan-A and other melanocyte differentiation antigens are presented by MHC class I on melanoma cells; cytotoxic T cells recognize and kill antigen-expressing tumor cells. Vaccination: Induction of T cell responses to recognize and clear melanoma cells presenting these antigens.